EGF has gained interest as a biomarker of renal disease because its decreased urinary excretion has been observed in nearly all rodent kidney injury models [20] and in various human kidney diseases [25], including diabetic nephropathy, IgA nephropathy, and lupus nephritis [14]. Here, EGF is linked to IgA glomerulonephritis.